The European Medicines Agency (EMA) has commenced the review of Sobi’s Kineret (anakinra) to treat Covid-19 in adults who are suffering from pneumonia and are at risk of severe respiratory failure. Kineret mitigates the immune system’s activity and is expected to decrease the inflammation and tissue damage caused by Covid-19. The EMA is set to provide its decision by October this year.

NRx Pharmaceuticals has reported that Zyesami (aviptadil) significantly prevented a sharp elevation in cytokines or cytokine storm when compared with placebo in Covid-19 patients in a Phase IIb/III clinical trial. The drug’s anti-cytokine effect was also linked to a significant reduction in 60-day mortality. NRx submitted these data to the US Food and Drug Administration to support its emergency use application for Zyesami to treat critically ill Covid-19 patients.

The Government of Taiwan has authorised Medigen Vaccine Biologics’ Covid-19 vaccine candidate for emergency use and manufacturing in the country. In clinical trials, the antibodies generated by Medigen’s candidate were “no worse” than those produced by AstraZeneca vaccines, without any major safety concerns, the health ministry said. With the approval, the company will scale up its production and a small volume of the vaccine doses are expected next month.